Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C | Q13936 | 4/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.41 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.37 |
| ▸ | CFD | P00746 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
| ▸ | DRD5 | P21918 | 2/20 | 0.35 |
| ▸ | HRH2 | P25021 | 2/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8220310 | 0.93 | CACNA1C (0.41) | CACNA1CCACNA2D1CACNA1BCACNB1ALDH1A1 | |
| SCHEMBL4379075 | 0.91 | CACNA1B (0.45) | CACNA1CCACNA1BPTGDR2DPP4DPP8 | |
| SCHEMBL4385524 | 0.88 | POLB (0.42) | ALDH1A1MAPTDPP4DPP8RORC | |
| SCHEMBL4382790 | 0.86 | PTGDR2 (0.42) | CACNA1CPTGDR2DPP4DPP8CACNA1F | |
| SCHEMBL4384414 | 0.85 | S1PR3 (0.36) | CACNA2D1CACNA1BCACNB1PTGDR2DPP4 | |
| SCHEMBL4387758 | 0.84 | FKBP1A (0.45) | ALDH1A1MAPTPTGDR2DPP4DPP8 | |
| SCHEMBL4381738 | 0.84 | KDM1A (0.39) | ALDH1A1MAPTDPP4DPP8KCNH2 | |
| SCHEMBL4382741 | 0.84 | DPP4 (0.36) | ALDH1A1MAPTPKMDPP4DPP8 | |
| SCHEMBL4376868 | 0.83 | DPP4 (0.36) | DPP4DPP8RORC | |
| SCHEMBL4381786 | 0.82 | DPP4 (0.39) | ALDH1A1DPP4DPP8RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | CACNA1C 26/4885CACNA2D1 209/4885CACNA1B 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.